Email Us
View Reports

BTG plc Company Profile

BTG plc Company Profile - Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation

  • ID : 4287818  |  
  • Published : Apr-2018  |  
  • Region : Global  |  
  • Pages : 30   |  
  • Publisher : Market Data Forecast

Company Overview:

BTG is a specialist healthcare company engaged in development of products the treatment of people with liver cancer, blood clots and varicose veins. The company has operations in Europe, the US, Canada and Australia.

The company operates through three business segments: interventional medicine (IM), specialty pharmaceuticals and licensing.

BTG's IM segment is engaged in the treatment of liver tumors, blood clots and varicose veins. Its product portfolio comprises drug-eluting beads, embolization beads, radiotherapy microspheres, EkoSonic Endovascular System and Varithena (polidocanol injectable foam).

The drug-eluting beads comprise DC Bead and DC BeadM1; embolization beads comprise Bead Block, LC Bead and LC BeadM1. The company's radioactive beads offers TheraSphere, a liver cancer therapy that consists of small radioactive glass microspheres that are delivered directly to liver tumors and used to treat patients with Hepatocellular carcinoma (HCC). BTG's EkoSonic Endovascular System is used for the treatment of blood clots. The company's Varithena is an injectable foam product used for the treatment of patients with symptoms and appearance of incompetent veins and visible varicosities of the great saphenous vein (GSV) system.

The company's specialty pharmaceuticals segment offers antidotes to treat snake envenomation and toxicity associated with medicines used for heart conditions and cancer. BTG offers a variety of acute care products that include CroFab (crotalidae polyvalent immune fab (ovine)), a drug used for the treatment of patients with North American pit viper envenomation; DigiFab (digoxin immune fab (ovine)), a drug used for the treatment for toxicity associated with the use of the heart medicine digoxin; and Voraxaze (glucarpidase), a drug used for the treatment of toxic plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function.

BTG's licensing segment generates royalties from technologies that have been licensed to others. The company licensed pharmaceutical products include Zytiga (abiraterone acetate), a product used for the treatment of advanced prostate cancer that is marketed by the Janssen Pharmaceutical Companies of Johnson & Johnson; Lemtrada (alemtuzumab), a product used for the treatment of sclerosis that is marketed by Sanofi and its subsidiary Genzyme; MRC humanization IP, an antibody humanization technology for various indications that is marketed by Medical Research Council; and two-part hip cup, a process of prosthetic hip joint replacement.

The company also offers named patient supplies, which enable healthcare professionals, on behalf of the patients, to access medicines approved or nearing approval in other countries before marketing authorization has been granted in the home country.

The company also offers named patient supplies, which enable healthcare professionals, on behalf of the patients, to access medicines approved or nearing approval in other countries before marketing authorization has been granted in the home country.

Scope of the Report

  • About the Company - Historical Details, Current Ownership Structure and basic overview of BTG plc in terms of revenue, net income, and operating income.
  • Financials - Details about BTG plc listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
  • Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.
  • Company SWOT Analysis - Outlines BTG plc’s strengths, weaknesses, and opportunities and threats facing the company.
  • Recent Developments - Showcases BTG plc’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
  • Strategic Evaluation - Provides an overview of BTG plc’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
  • Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.

Key Questions Answered

  • What domain does BTG plc operate and what are key points about it?
  • What is the product / service portfolio of BTG plc?
  • How has BTG plc performed financially from the 2013?
  • How does BTG plc rank among its peers in terms of revenue and market share?
  • What are BTG plc strengths and weaknesses and what opportunities and threats does it face?
  • What are BTG plc’s main growth strategies and how successful has the company been at implementing them?
  • What is the in-house technical capability of BTG plc? Where does it procure / outsource it?

Reasons to buy

  • Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
  • Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost
  • 12 hour delivery time fulfilling your urgent requests as per your requirement
  • On-demand customization options that can completely cater to your needs by focusing the report onto given specifics

1. About the Company

1.1 History and Basic Facts

1.2 Ownership Structure and Key Executives

1.3 Head Office

1.4 Other Locations & Subsidiaries

1.5 List of Competitors

1.6 Employee Count & Distribution

2. Financials

2.1 Company Type (Listed / Unlisted)

2.2 Annual Statements

2.3 Key Financial Highlights

2.4 Region-wise Breakdown

3. Product / Services

3.1 Overview

3.2 Description

4. SWOT Analysis

4.1 SWOT Overview

4.2 Strengths

4.3 Weaknesses

4.4 Opportunities

4.5 Threats

5. Recent Developments

5.1 Mergers & Acquisitions

5.2 Partnerships, Collaborations & Joint Ventures

5.3 New Product Launches

5.4 Business Expansion / Divestment

6. Strategic Evaluation

6.1 Corporate Strategy

6.2 Legal Issues

6.3 Analyst Outlook

7. Technology Landscape

7.1 Industry

7.1.1 Industry Snapshot

7.1.2 IT Spend

7.1.3 Key Information Technology Trends

7.2 Company

7.2.1 IT Overview

7.2.2 Key IT Technologies

7.2.3 Recent IT Initiatives

7.2.4 IT Outsourcing Engagements

7.2.5 Key IT Management

7.2.6 CIO/CTO Profile

Appendix

  • Methodology
  • About Us
  • Contact Us
  • Disclaimer

Fig.1: Company Snapshot

Fig.2: Locations Listing on Map

Table.1: Ownership Structure

Table.2: List of Competitors

Table.3: Annual Statements

Table.4: Key Financial Highlights

Table.5: Region-wise Breakdown

Table.6: Product/Services Overview

Table.7: Mergers & Acquisitions

Table.8: Partnerships, Collaborations & Joint Ventures

Table.9: New Product Launches

Table.10: Business Expansion / Divestment

Table 11: IT Budgets

Table 12: Key IT Management (CIO / CTO)

Table 13: IT Deals undertaken in the past years

Purchase this Market Research Report

REACH OUT TO US

Call us on : +1 888 709 8757

Drop us an email at : info@researchcosmos.com

HAVE A QUESTION?